PH12020551185A1 - Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation - Google Patents
Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriationInfo
- Publication number
- PH12020551185A1 PH12020551185A1 PH12020551185A PH12020551185A PH12020551185A1 PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1 PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A PH12020551185 A PH 12020551185A PH 12020551185 A1 PH12020551185 A1 PH 12020551185A1
- Authority
- PH
- Philippines
- Prior art keywords
- atopic dermatitis
- treatment
- nemolizumab
- excoriation
- moderate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628714P | 2018-02-09 | 2018-02-09 | |
| PCT/IB2019/051051 WO2019155427A1 (en) | 2018-02-09 | 2019-02-08 | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020551185A1 true PH12020551185A1 (en) | 2021-05-17 |
Family
ID=65729402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020551185A PH12020551185A1 (en) | 2018-02-09 | 2020-08-05 | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
Country Status (23)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202535464A (zh) * | 2023-11-02 | 2025-09-16 | 日商丸寶股份有限公司 | 醫藥組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| DK1188830T3 (da) | 1999-06-02 | 2010-04-26 | Chugai Pharmaceutical Co Ltd | Nyt hæmopoietinreceptorprotein NR10 |
| EP1858924A1 (en) * | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| CN105859889B (zh) * | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| WO2017093857A1 (en) * | 2015-11-30 | 2017-06-08 | Anacor Pharmaceuticals, Inc. | Topical pharmaceutical formulations for treating inflammatory-related conditions |
-
2019
- 2019-02-08 PL PL19710488.8T patent/PL3749353T3/pl unknown
- 2019-02-08 HR HRP20251101TT patent/HRP20251101T1/hr unknown
- 2019-02-08 FI FIEP19710488.8T patent/FI3749353T3/fi active
- 2019-02-08 SG SG11202007558YA patent/SG11202007558YA/en unknown
- 2019-02-08 MX MX2020008193A patent/MX2020008193A/es unknown
- 2019-02-08 DK DK19710488.8T patent/DK3749353T3/da active
- 2019-02-08 LT LTEPPCT/IB2019/051051T patent/LT3749353T/lt unknown
- 2019-02-08 EP EP25189672.6A patent/EP4644424A3/en active Pending
- 2019-02-08 RU RU2020129578A patent/RU2758378C1/ru active
- 2019-02-08 PT PT197104888T patent/PT3749353T/pt unknown
- 2019-02-08 JP JP2020542801A patent/JP7777921B2/ja active Active
- 2019-02-08 CA CA3090062A patent/CA3090062A1/en active Pending
- 2019-02-08 AU AU2019219608A patent/AU2019219608B2/en active Active
- 2019-02-08 CN CN201980024489.7A patent/CN112040976A/zh active Pending
- 2019-02-08 SI SI201930960T patent/SI3749353T1/sl unknown
- 2019-02-08 ES ES19710488T patent/ES3049513T3/es active Active
- 2019-02-08 EP EP19710488.8A patent/EP3749353B1/en active Active
- 2019-02-08 WO PCT/IB2019/051051 patent/WO2019155427A1/en not_active Ceased
- 2019-02-08 BR BR112020016144-6A patent/BR112020016144A2/pt unknown
- 2019-02-11 TW TW108104519A patent/TWI856006B/zh active
- 2019-02-11 TW TW113115277A patent/TWI923998B/zh active
-
2020
- 2020-08-05 PH PH12020551185A patent/PH12020551185A1/en unknown
- 2020-08-05 IL IL276524A patent/IL276524A/en unknown
- 2020-08-07 US US16/988,554 patent/US12435147B2/en active Active
- 2020-08-07 CL CL2020002050A patent/CL2020002050A1/es unknown
-
2023
- 2023-09-21 JP JP2023155476A patent/JP2023182632A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151311A patent/JP2025176134A/ja active Pending
- 2025-09-12 US US19/327,709 patent/US20260008859A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200182A patent/AU2026200182A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004259A (es) | Inhibidores de mek para el tratamiento de infecciones por hantavirus. | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2017014020A (es) | Terapia antimicrobiana. | |
| MX376691B (es) | Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea. | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| PH12019550265B1 (en) | Composition comprising mannose oligosaccharide and process for making same and use thereof | |
| PH12017501300A1 (en) | Novel iodophor composition and methods of use | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| EP4640237A3 (en) | Macrophage-based therapy for use in the treatment of acute liver injury | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| EP4644424A3 (en) | Treatment of atopic dermatitis with moderate to severe excoriation | |
| WO2020032902A3 (en) | Aksolotl blastema for use in the treatment of wounds and burns |